ASX Share rice
Sat 08 Aug 2020 - 04:30:am (Sydney)

GTG Share Price

GENETIC TECHNOLOGIES LIMITEDGTGPharmaceuticals, Biotechnology & Life Sciences

GTG Company Information

Name:

Genetic Technologies Limited

Sector:

Healthcare

Industry:

Diagnostics & Research

GIC Industry:

Life Sciences Tools & Services

GIC Sub Industry:

Life Sciences Tools & Services

Address:

60-66 Hanover Street Fitzroy VIC Australia 3065

Phone:

61 3 8412 7000

Interim CEO & Director:

Dr. Jerzy Muchnicki

Scientific Director:

Dr. Richard Allman

Consultant:

Mr. Paul Keith Mathieson Viney B. Bus, FCPA, FGIA, FCI

Chief Financial Officer:

Mr. Phillip Hains C.A., M.B.A., B Bus, CA, MBA

Chief Operating Officer:

Mr. Stanley Sack

Company Overview:

Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. The company also engages in the development of various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer name. In addition, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was founded in 1989 and is headquartered in Fitzroy, Australia.

GTG Share Price Information

Shares Issued:

8.26B

Market Capitalisation:

$74.36M

Revenue (TTM):

$7.63K

Earnings per Share:

$-0.002

Operating Margin (TTM):

$-858.07

Return On Assets (TTM):

$-0.97

Return On Equity (TTM):

$-2.02

Quarterly Revenue Growth (YOY):

-0.968

Gross Profit(TTM):

$-250,823

Diluted Earnings Per Share (TTM):

$-0.002

GTG CashFlow Statement

CashFlow Date:

2020-06-30

Investments:

$64K

Capital Expenditures:

$16K

GTG Income Statement

Income Date:

2019-06-30

Income Before Tax:

$-6,425,604

Net Income:

$-6,425,604

Gross Profit:

$-250,823

Operating Income:

$-6,161,153

Other Operating Expenses:

$-993,979

Interest Expense:

$20.03K

Total Revenue:

$25.44K

Total Operating Expenses:

$6.19M

Cost Of Revenue:

$276.27K

GTG Balance Sheet

Balance Sheet Date:

2019-06-30

Total Liabilities:

$1.49M

Total Stockholder Equity:

$1.77M

Other Current Liabilities:

$160.01K

Total Assets:

$3.27M

Common Stock:

$125.50M

Other Current Assets:

$213.30K

Retained Earnings:

$-129,737,550

Other Liabilities:

$809

Cash:

$2.13M

Total Current Liabilities:

$1.49M

Property - Plant & Equipment:

$69.33K

Net Tangible Assets:

$1.77M

Total Current Assets:

$3.20M

Net Receivables:

$16.53K

Short-Term Investments:

$69.33K

Inventory:

$31.87K

Accounts Payable:

$590.23K

Non Currrent Assets (Other):

$69.33K

Short-Term Investments:

$69.33

Non Current Liabilities Total:

$809

GTG Share Price History

GTG News

21 Jul, 2020
MELBOURNE, Australia, July 20, 2020 -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests,.
16 Jul, 2020
MELBOURNE, Australia, July 16, 2020 -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests,.
15 Jul, 2020
Highlights Genetic Technologies has filed a provisional patent for its COVID-19 Severity Risk Test with the Patent Office in AustraliaThe COVID-19 Severity Risk Test.
23 Jun, 2020
MELBOURNE, Australia, June 23, 2020 -- Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”) is pleased to announce that its.
18 Jun, 2020
Issuance of US Patent No: US 10,683,549, Methods for assessing risk of developing breast cancer.Filed provisional patent for its COVID-19 Severity Risk Test, 2020901739 –.
04 Jun, 2020
Potential Genetic Technologies Limited (ASX:GTG) shareholders may wish to note that the Independent Non-Executive...
29 May, 2020
Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, today announced the closing of its previously announced public offering of 3,500,000 American Depositary Shares (“ADSs”), each representing six hundred (600) of the Company’s ordinary shares, at an effective purchase price of $2.00 per ADS, and 500,000 pre-funded warrants, at an effective purchase price of $1.9999 per pre-funded warrant, for aggregate gross proceeds of approximately $8.0 million. The Company  intends to use the net proceeds from this offering to support the introduction and distribution of our new products in the United States, for general product research and development, including the development of polygenic risk tests, and reimbursement studies with TGen in the United States, for implementation of our consumer initiated testing platform, preparation for potential COVID-19 testing, COVID-19 risk test for developing serious disease from contracting COVID-19, for working capital and new equipment purchases.
26 May, 2020
Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, today announced that it has priced a public offering of 4,000,000 American Depositary Shares (“ADSs”) (or ADS equivalents), each representing six hundred (600) of the Company’s ordinary shares, at an effective purchase price of $2.00 per ADS (or ADS equivalent). H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds from this offering are expected to be $8.0 million, before deducting the placement agent’s fees and other offering expenses payable by the Company.
22 May, 2020
To accompany that process, the Company will be working with its Consumer Initiated Testing (CIT) platform supplier to generate online product content to support sales activities in the USA. Leveraging Genetic Technologies’ core expertise in predictive risk modelling, the Company has also now completed analysis of the early, available genomic and phenotypic data from 1,500 COVID-19 patients.
20 May, 2020
Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) is to commence accelerating development of a polygenic risk score (PRS) test to predict an individual’s risk of developing life-threatening complications should they become infected with COVID-19. Dr George Muchnicki CEO said "GENE has secured a data set of over 1,500 patients who experienced COVID-19 and we intend on leveraging our core expertise in predictive risk modelling, to analyse the early, available genomic and phenotypic data from those COVID-19 patients with a view to developing a comprehensive predictive model to identify those patients most likely to require hospitalization, should they become infected with the COVID-19 virus."
17 Apr, 2020
Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”) has developed a detailed implementation plan to enable a temporary transition of our genetic testing laboratory to a high-throughput COVID-19 testing laboratory, should it be required by Government agencies to assist with demand. Initial work to identify laboratory workflows, instrument modification, laboratory compliance for biologics and contaminated materials handling has commenced. This COVID-19 testing implementation plan has been developed as a result of the Company’s expectation of an increase in demand for COVID-19 testing and is not based on any existing agreement to provide COVID-19 testing.
01 Apr, 2020
Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”), provides the following update to the market. Breast Cancer and Colorectal Cancer tests commissioned, and sales commenced First Quarter 2020 with over 100 test kits distributed.
14 Mar, 2020
The Letter indicates that Listing Rule 5815(d)(4)(B) does not permit an issuer that is deficient in stockholders’ equity to present a plan of compliance to the Nasdaq Staff if such issuer has failed to comply with that provision within one year of a Hearing Panel (the “Panel”) determination of compliance. On November 6, 2019, the Company received a letter from Nasdaq notifying the Company that it had regained compliance with the Equity Rule (the “Compliance Letter”).
12 Mar, 2020
While it may not be enough for some shareholders, we think it is good to see the Genetic Technologies Limited...
13 Jan, 2020
MELBOURNE, Australia, Jan. 13, 2020 -- Genetic Technologies (ASX: GTG; NASDAQ: GENE), a leader in the development of genetic risk assessment tests, recently announced the.
07 Jan, 2020
Molecular diagnostics company Genetic Technologies Limited (ASX: GTG, NASDAQ: GENE) is pleased to advise that its third-generation breast cancer test (GeneType for Breast Cancer) is on track for commercial release in the Unites States (US) in Q1 2020. Genetic Technologies expects to take advantage of the growing confidence and interest in genomic testing, and its first to market status in the US market. GeneType for breast cancer (BC) is on track for release in the US in Q1 (2020) via a soft launch across 20 centres in 8 States, which demonstrates the strong support from practitioners for the introduction of the company’s third generation test incorporating mammography data.